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Background: The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed
by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete
response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review.
Patients and methods: Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC),64 cycles of Bev
(BevþD-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden
(RCB) class.
Results: A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2–4.4)]. DFS and OS were similar across
treatment arms [DFS hazard ratio (HR)¼1.18 (95% CI 0.89–1.57), P¼ 0.25; OS HR¼ 1.26 (95% CI 0.90–1.76), P¼ 0.19). Both local
pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients
who achieved a pCR [DFS HR¼ 0.38 (95% CI 0.23–0.63), P< 0.001; OS HR¼ 0.43 (95% CI 0.24–0.75), P¼ 0.003]. However, signifi-
cant heterogeneity was observed (P¼ 0.02); larger improvements in DFS were obtained with a pCR achieved with D-FEC than a
pCR achieved with BevþD-FEC. As RCB class increased, significantly worse DFS and OS was observed (P for trend<0.0001),
which effect was most marked in the ER negative group.
Conclusions: The addition of short course neoadjuvant Bev to standard chemotherapy did not demonstrate a DFS or OS
benefit. Achieving a pCR with D-FEC is associated with improved DFS and OS but not when pCR is achieved with BevþD-FEC.
At the present time therefore, Bev is not recommended in early breast cancer.
ClinicalTrials.gov number: NCT01093235.
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Introduction
The ARTemis trial was designed to test the hypothesis that adding
bevacizumab (Bev) [1, 2] to standard neoadjuvant chemotherapy
would improve pathological complete response rates (pCR), and
longer-term outcomes for HER2 negative early breast cancer.
Assessed by a two-reader blinded review of local pathology
reports, the addition of four cycles of Bev to D-FEC was found to
improve pCR rates (22% for BevþD-FEC patients, 17% for
D-FEC patients, adjusted P¼ 0.03) [3]. Other neoadjuvant trials
(GeparQuinto [4], CALGB 40603 [5] and NSABP-B40 study [6])
also showed an improvement in pCR rates with the addition of
Bev to neoadjuvant chemotherapy. However, adjuvant Bev in the
BEATRICE study in TNBC patients [7] and in the ECOG 5103
study [8], showed no improvement in invasive disease-free sur-
vival (IDFS) or overall survival (OS). Both of these adjuvant trials
used a year of Bev in the experimental arm, as did the NSABP-
B40. In contrast, shorter courses of Bev were used in the other tri-
als: four cycles at 15mg/kg every 3weeks (q3w) in ARTemis; eight
cycles at 15mg/kg q3w in GeparQuinto; and nine cycles at 10mg/
kg q2w in CALGB 40603.
A central pathological review of diagnostic and surgical
excision histopathology slides was undertaken (manuscript in
press 2017) which included Residual Cancer Burden (RCB)
class [9]. Using these analyses, we present here the secondary
endpoints of DFS and OS for the ARTemis trial to assess
whether the increase in pCR rate results in improved longer-
term outcomes.
Methods
ARTemis is an investigator designed and led, open label randomized,
phase III trial approved by the South-East England Multi-Centre
Research Ethics Committee and the Research and Development depart-
ments at all participating centres. It was granted a Clinical Trials
Authorization from the Medicines and Healthcare products Regulatory
Agency on 25 February 2009. Trial co-ordination was supported by a
Cancer Research UK project grant (CRUK/08/037). An unrestricted edu-
cational grant and free Bev was provided by Roche and an unrestricted
educational grant by Sanofi.
Study design
Full details of the design, sample size, eligibility, stratification and treat-
ments have been described elsewhere [3]. Eligibility included women
with a histological diagnosis of non-metastatic HER2 negative invasive
breast cancer, and a radiological tumor size of>20mm with or without
axillary involvement. All patients provided written informed consent and
could commence chemotherapy within oneweek of randomization.
Patients with inflammatory cancer, T4 tumors with direct extension to
the chest wall or skin, and ipsilateral supraclavicular lymph node involve-
ment were eligible with any size of primary tumor. The two randomized
treatments were: three cycles of docetaxel (100mg/m2 once every 21
days) followed by three cycles of fluorouracil, epirubicin, and cyclophos-
phamide (500 : 100 : 500mg/m2) once every 21 days (D-FEC), with or
without four cycles of Bev (15mg/kg) (BevþD-FEC) commencing with
the first cycle of docetaxel.
Patients
Patients were randomly assigned (1 : 1) by telephone to the Warwick
Clinical Trials Unit. Using a central computerized minimization proce-
dure, stratification was by age (50 :>50), ER status [strongly positive
(Allred score 6–8): weakly positive (Allred score 3–5): negative (Allred
score 2)], total tumor size (5 cm :>5 cm), clinical involvement of
axillary lymph nodes (yes : no) and disease type (inflammatory and/or
locally advanced: neither).
Central pathology specimen review
Two breast pathologists on the trial management group reviewed, blind
to local pathology reports and patient outcomes, all collected histopa-
thology slides for response (pCR and RCB) [9].
Statistical analysis
OS was calculated from date of randomization to date of death from any
cause, or date of censoring if alive. DFS was calculated from date of ran-
domization to date of first relapse (loco-regional or distant, not including
DCIS); to date of death in women dying without invasive relapse; or to
date of censoring in women alive and disease-free. Survival curves were
constructed using Kaplan–Meier methodology and assessed using log-
rank tests. Cox-proportional hazards modelling was used to investigate
treatment effects, whilst adjusting for stratification variables. Hazard
ratios of treatment effects on the risk of relapse and death for each of the
stratified subgroups were displayed on HR plots [10]. To assess the asso-
ciation between response to neoadjuvant treatment and DFS and OS, a
landmark analysis was undertaken recalculating times from date of sur-
gery. Pathological response rates were assessed across randomized treat-
ment arms using v2 tests, with continuity correction where appropriate,
and logistic regression to adjust for stratification factors.
We report the protocol-stated pre-planned interim analysis of DFS
and OS with at least 120 events (median follow-up 3 years). All analyses
were undertaken by Warwick Clinical Trials Unit with SAS statistical
software (version 9.3). Protocol violators were analyzed within their
randomized groups on an intention-to-treat basis. All reported P-values
are two-sided. ARTemis is registered with EudraCT (2008-002322-11),
ISRCTN (68502941), and ClinicalTrials.gov (NCT01093235).
Results
Patient characteristics
A total of 800 patients were randomized into ARTemis between
May 2009 and January 2013; 399 to BevþD-FEC, 401 to D-FEC
(Figure 1 and Table 1). Patient characteristics were balanced
across randomized treatment arms [3]. The distribution of
important prognostic factors in the subgroups with available cen-
tral pathology review was similar to the full trial (Table 1).
Central pathology review and pCR rates
The original analysis of the primary endpoint of pCR on the 781
patients who had surgery within the trial used a two-reader inde-
pendent review of local pathology reports (Figure 1). This
allowed detection of absolute differences between treatment arms
in the pCR rates>10% at the 5% (two-sided) level of significance
(85% power). Histopathology slide retrieval was successful in
obtaining a full slide set in 681/781 patients (87%). This ensured
that the central pathological review allowed detection of the same
10% differences (power reduced to 80%). Patients with positive
pre-treatment sentinel lymph node biopsy (SLNB) were excluded
from RCB assessment, as per the guidelines [9] leaving 587/681
patients (86%) with calculated RCB (Figure 1).
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In the original publication, based on the 2-reader report review,
pCR was reported for 153/781 patients (20%) [3]. For patients
who had central pathological review (n¼ 681), pCR was reported
in 130/681 patients (19%), with a higher pCR rate for BevþD-
FEC patients [77/344 (22%) versus 53/337 (16%) for D-FEC
patients; adjusted P¼ 0.03; Table 2]. Amongst the 587 patients
with assessable RCB, treatment with Bev resulted in a shift towards
better (lower) RCB classes (adjusted P for trend¼ 0.004; Table 2).
Disease-free and overall survival
At the data lock (14 April 2016), 136/800 (17%) patients had died
(Figure 1). The median follow-up for alive patients was 3.5 years,
with 82% of alive patients having>3 years follow-up. The main
cause of death was breast cancer [98% (133/136) of patients who
died]. Seventy-two patients have a local relapse, and 151 patients
a distant relapse, predominantly in the bone, liver and/or lung
(81% of patients who have a distant relapse). Forty-seven patients
reported a local and distant relapse. There are 191 events in the
DFS analysis (24%).
There were no significant differences detected in DFS or OS
between the two randomized treatment arms [DFS HR 1.18 (95%
CI 0.89–1.57), P¼ 0.25, Figure 2A; OS HR 1.26 (95% CI 0.90–
1.76), P¼ 0.19, Figure 2B]. There was evidence of heterogeneity
only in the treatment effect on DFS for patients with clinically
negative nodes at diagnosis (heterogeneity P¼ 0.02, not adjusted
for multiple comparisons) (supplementary Figure S1A, available
at Annals of Oncology online). Otherwise no heterogeneity was
Randomized
(n=800)
Assigned to Bev+D-FEC
(n=399)
Central review of local pathology reports
Primary endpoint information available (pCR Y/N)
(n=781)
Withdrew consent for FU prior to
surgery (n=13)
Did not undergo surgery (n=5)
No nodal investigation at surgery (n=1)
Incomplete pathology
sample set provided
(n=100)
Positive pre-CT SLNB
(n=94)
Central review of pathology specimens
Primary endpoint information available (pCR Y/N)
(n=681)
RCB score and class calculated
(n=587)
pre-CT SLNB=pre-chemotherapy sentinel lymph node biopsy; RCB=residual cancer burden;
DFS=disease-free survival; OS=overall survival
Secondary  endpoint analysis of DFS and OS (n=800)
136 (17%) deaths, 191 (24%) DFS events
Median follow-up of alive patients = 3.5 years (IQR 3.2 – 4.4 years)
82% of alive patients with > 3 years follow-up
Assigned to D-FEC
(n=401)
Figure 1. Consort diagram.
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observed in the treatment effect on DFS and OS across all patient
characteristics (supplementary Figure S1B, available at Annals of
Oncology online). However, there appeared to be a slightly worse
DFS and OS for ER strongly positive patients treated with Bev
(supplementary Figure S2, available at Annals of Oncology
online).
DFS and OS from surgery by pCR
The landmark analysis, investigating the effect of pathological
response on DFS and OS, included 677/681 patients; 109/677
(16%) subsequently died, and 157/677 (23%) subsequently had a
DFS event. Analysis of DFS events in the pCR group (supplemen-
tary Table S1, available at Annals of Oncology online) demon-
strated that, although more patients achieved a pCR in the
BevþD-FEC arm (22% versus 16% for D-FEC), 16/77 (16%)
had a DFS event compared with only 3/52 (6%) in the D-FEC
arm.
There was a significant improvement in both DFS and OS for
patients obtaining pCR [DFS HR 0.38 (95% CI 0.23–0.63),
P< 0.001; supplementary Figure S3A, available at Annals of
Oncology online; OS HR 0.43 (95% CI 0.24–0.75), P¼ 0.003;
supplementary Figure S3D, available at Annals of Oncology
online]. However, there was significant heterogeneity in treat-
ment effect on DFS between patients achieving pCR or not
(P¼ 0.02) and according to RCB class (P¼ 0.03) (Figure 3A).
Importantly, patients achieving pCR in the BevþD-FEC arm
had a risk of a DFS event that was 2.99-fold higher (95% CI
1.20–7.45) than that for patients achieving pCR in the D-FEC
arm (Figure 3A). Similar findings, although non-significant,
were seen for OS (P¼ 0.19 for pCR and P¼ 0.05 for RCB class)
(Figure 3B). DFS and OS curves plotted by treatment arm dem-
onstrated this larger improvement in D-FEC patients (supple-
mentary Figure S3C and F, B and E, available at Annals of
Table 1. Patient characteristics and response to treatment
Patient characteristics Full trial
population
Central pathology sample with
primary endpoint assessable
Central pathology sample
with RCB assessable
(n5800) (n5681) (n5587)
n (%) n (%) n (%)
Randomized treatment BevþD-FEC 399 (50) 344 (51) 290 (49)
D-FEC 401 (50) 337 (49) 297 (51)
Age 50 years old 543 (68) 458 (67) 393 (67)
>50 years old 257 (32) 223 (33) 194 (33)
ER status Negative (Allred score 0–2) 248 (31) 211 (31) 194 (33)
Weakly positive (Allred score 3–5) 75 (9) 68 (10) 60 (10)
Strongly positive (Allred score 6–8) 477 (60) 402 (59) 333 (57)
Tumor size 50mm 635 (79) 541 (79) 472 (80)
>50mm 165 (21) 140 (21) 115 (20)
Clinical involvement of Yes 417 (52) 354 (52) 299 (51)
axillary nodes No 383 (48) 327 (48) 288 (49)
Inﬂammatory or locally Yes 149 (19) 120 (18) 103 (18)
advanced disease or both No 651 (81) 561 (82) 484 (82)
Response to Treatment
pCR Yes – 130 (19) 121 (21)
No – 551 (81) 466 (79)
RCB class 0 – – 121 (21)
1 – – 90 (15)
2 – – 290 (49)
3 – – 86 (15)
pCR, central pathology sample review shows pathological complete response in all breast tumors AND absence of disease in all removed axillary lymph
nodes; RCB, residual cancer burden.
Table 2. Response rates from the central review of pathology specimens,
across randomized treatment arms
Bev1D-FEC D-FEC
n (%) n (%) P (adjusted Pa)
pCR (n ¼681)
Yes 77 (22) 53 (16) 0.03 (0.03)
No 267 (78) 284 (84)
RCB class (n ¼587)
0 72 (25) 49 (16) 0.004 (0.004)
1 46 (16) 44 (15)
2 138 (47) 152 (51)
3 34 (12) 52 (18)
aAdjusted for the ﬁve stratiﬁcation variables.
pCR, pathological complete response in all breast tumors AND absence
of disease in all removed axillary lymph nodes; RCB, residual cancer
burden.
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Oncology online). As RCB class increased, significantly worse
DFS and OS was observed (both P for trend<0.0001, supple-
mentary Figure S4A and D, available at Annals of Oncology
online) and, similar to pCR, with differing treatment effects
across the classes (DFS heterogeneity P¼ 0.03, Figure 3A; OS
heterogeneity P¼ 0.05, Figure 3B). An additional analysis of
DFS and OS by RCB for ER groups is shown (supplementary
Figure S5, available at Annals of Oncology online).
Discussion
The ARTemis trial results reported here demonstrate no advant-
age for short course neoadjuvant Bev in terms of DFS and OS at a
median follow-up of 3.5 years and these results are similar to
those of GeparQuinto [11] and CALGB-40603 [12]. It has been
shown in most neoadjuvant breast cancer trials that longer term
outcomes, analyzed by treatment arm, fail to show a benefit even
1.0A
B
Su
rv
iva
l p
ro
ba
bi
lity
0.8
0.6
0.4
0.2
0
0 1
Disease-free survival from randomization (years)
2 3 4 5
BEV+D FEC
Numbers at risk
399
401
374
375
321
331
249
BEV+D FEC
+ Censored
+ Censored
Bev+D-FEC
D-FEC
399
#
401
102 (26%) 1.18 (0.89-1.57) 0.25
#DFS events HR* (95% CI) P*
89 (22%)
Bev+D-FEC
D-FEC
399
#
401
74 (19%) 1.26 (0.90-1.76) 0.19
#dead HR* (95% CI) P *
62 (15%)
D FEC
258
122
124
40
40
0 1
Overall survival from randomization (years)
*Adjusted for stratification variables
2 3 4 5
Numbers at risk
399
401
386
387
356
365
273
280
130
134
45
46
D FEC
1.0
Su
rv
iva
l p
ro
ba
bi
lity
0.8
0.6
0.4
0.2
0
BEV+D FEC
D FEC
BEV+D FEC D FEC
Figure 2. Survival curves by randomized treatment arm. (A) Disease-free survival and (B) Overall survival.
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Figure 3. Treatment effect by pathological response. (A) Disease-free survival from surgery and (B) Overall survival from surgery.
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when there are significant improvements in pCR rates. It is now
understood that this is due to a complexity of interacting factors
[13–15], the most obvious of which is the smaller number of
patients required in neoadjuvant trials. Only one neoadjuvant
trial in HER2 positive breast cancer adding trastuzumab to stand-
ard chemotherapy showed improved long term outcomes by
treatment arm [16].
Pooled analyses [17, 18] have shown that patients achieving
pCR have significantly better DFS and OS than other patients.
However, ARTemis shows that gaining a pCR for patients with
the addition of Bev does not appear to have this benefit, and the
outcomes for these patients are not significantly better than for
those not achieving a pCR. This is clearly demonstrated both by
the Kaplan–Meier DFS and OS curves by pCR and treatment
arms (supplementary Figure S3, available at Annals of Oncology
online), and in the forest plots (Figure 3). This result has led to
our hypothesis [3] that although Bev improves pCR rates by its
effect in the angiogenesis-dependent primary tumor, it has no
effect on putative angiogenesis-independent micro-metastatic
disease. This hypothesis would also explain the negative long-
term results from GeparQuinto and CALGB-40603 [12, 13] and
adjuvant BEATRICE and ECOG studies [7, 8]. Similar negative
results have been found in adjuvant studies in colorectal cancer
[19] and melanoma [20]. In contrast, in epithelial ovarian cancer
(EOC) in the first line setting [21, 22] positive long-term results
have been shown probably for two reasons; firstly the majority of
patients had macroscopic residual disease post-surgery which is
angiogenesis-dependent; and secondly there may be an autocrine
effect of VEGF directly on receptors on ovarian cancer cells [23].
Intriguingly, the ARTemis data hint at the possibility that
patients in the experimental arm do non-significantly but slightly
worse than the standard arm (supplementary Figure S1, available
at Annals of Oncology online). One explanation is the possible
increased populations of classically chemo-resistant breast cancer
stem cells in tumors due to the hypoxia generated by Bev [24]. In
addition, there is possibly a group for whom Bev is having a detri-
mental effect. This has been reported in EOC where an ‘immuno-
logical signature’ with a better prognosis was associated with a
negative interaction with Bev [25]. We plan translational research
to discover whether there are similar molecular signatures in
ARTemis.
Our central pathology review and analysis of RCB classes has
provided some interesting additional results. Bev shows a benefit
in terms of the proportion of patients achieving pCR, but there is
no improvement in survival for patients achieving a pCR. Central
review confirms these findings from the two-reader report review
[3].
In conclusion the ARTemis trial shows that, although the addi-
tion of Bev to taxane-anthracycline-based chemotherapy
increases pCR rates, it does not provide a corresponding benefit
in terms of DFS and OS.
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